Infinium Pharmachem MD, chairman and AGM

Infinium Pharmachem board of directors

At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

Statutory auditor

Named in the results for the quarter to Mar 2026.

Ashok Rajpara & CoPeer-review certificate valid to Dec 2026

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Infinium Pharmachem AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Infinium Pharmachem share news and announcements

Postal ballot, 26 Sep 2026

1,109 shareholders on the register on 21 Aug 2026; votes counted by RAJESH C. TARPARA / RTBR & Associates.The company's voting result (opens in a new tab)

MIGRATION OF THE EQUITY SHARES OF THE COMPANY FROM NSE EMERGE PLATFORM TO THE MAINBOARD OF NSE
Special
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 77.56% · promoters 97.76% · institutions 100.00% · other public 39.82%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 17 Sep 2026, 7 resolutions

1,112 shareholders on the register on 10 Sep 2026; present: 8 promoters and 10 others; votes counted by RAJESH C. TARPARA / RTBR & Associates.The company's voting result (opens in a new tab)

To receive, consider and adopt the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors and Auditors thereonMoreLess
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.40% · promoters 97.76% · institutions 100.00% · other public 22.14%
To appoint a Director in place of Mr. Mitesh Lavjibhai Chikhaliya (DIN: 03342934), who retires by rotation and being eligible, offers himself for re-appointment
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.40% · promoters 97.76% · institutions 100.00% · other public 22.14%
Ratification of remuneration of the Cost Auditors for the financial year 2026-27
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 71.40% · promoters 97.76% · institutions 100.00% · other public 22.14%
Approval of Material Related Party Transactions of the Company
OrdinaryPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 7.95% · promoters 0.00% · institutions 100.00% · other public 22.14%
Revision in remuneration of Mr. Sanjaykumar Viththalbhai Patel, Managing Director (DIN: 00370715) of the Company
SpecialPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 61.15% · promoters 81.96% · institutions 100.00% · other public 22.14%
Revision in remuneration of Mr. Pravin Bhadabhai Madhani, Director (Executive) (DIN: 00370791) of the Company
SpecialPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 49.75% · promoters 64.40% · institutions 100.00% · other public 22.14%
Revision in remuneration of Mr. Mitesh Lavjibhai Chikhaliya, Director (Executive) (DIN: 03342934) of the Company
SpecialPromoters have an interest in it
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 66.63% · promoters 90.40% · institutions 100.00% · other public 22.14%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Dealings with its subsidiaries, promoters, directors and their firms, reported every half-year.Promoters and their stake

Half-year to Mar 2026: ₹8 Cr7 dealings
Half-year to Sep 2025: ₹14,78,083 Cr9 dealings

Between	Dealing
Infinium Pharmachem Limited and Shanghai Tajilin Industrial Co. LtdJOINT VENTURE	Sale of goods or services	30.00	7.01	11.97	4.93
Infinium Pharmachem Limited and Mr. Sanjay PatelMANAGING DIRECTOR	Remuneration	0.86	0.21	0.02	0.02
Infinium Pharmachem Limited and Mr. Pravin MadhaniDIRECTOR	Remuneration	0.86	0.21	0.02	0.02
Infinium Pharmachem Limited and Mr. Mitesh ChikhaliyaDIRECTOR	Remuneration	0.86	0.21	0.02	0.02
Infinium Pharmachem Limited and Infinium Green Energy Private LimitedSUBSIDARY	Purchase of goods or services	2.00	0.04	₹66,000	0.01
Infinium Pharmachem Limited and Infinium Green Energy Private LimitedSUBSIDARY	Any other transactionELECTRICITY EXPENSE(REIMBURSE)The actual amount is Rs. 0.078 lakhs but utility is not accepting/ validating the same so we have mentioned Rs. 0.78 lakhs.	–	₹78,000	0.00	0.00
Infinium Pharmachem Limited and Infinium Healthcare Private LimitedSUBSIDARY	Any other transactionELECTRICITY EXPENSE(REIMBURSE)The actual amount is Rs. 0.018 lakhs but utility is not accepting/ validating the same so we have mentioned Rs. 0.18 lakhs.	–	₹18,000	0.00	0.00

The 7 largest of 7 dealings in the half-year to Mar 2026, ₹ crore.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

Received
Resolved

Open at the quarter's end

None open at any quarter's end.

The filing has a part on fines and penalties: No
The filing has a part on tax disputes: No

The company's own answers in its filing.

How money raised was used

Reported for the quarter to Mar 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.

Raised	Amount raised	For	Set aside	Spent	Spent elsewhere	Reason and comments
Public IssuesMar 2023	25.26	Registrations, Reach - Europe, other marketing expenses	1.13	1.13	No	No Deviation
Public IssuesMar 2023	25.26	Repayment of loan	3.92	3.92	No	No Deviation
Public IssuesMar 2023	25.26	Expansion of Existing Unit-2	5.05	5.05	No	No Deviation
Public IssuesMar 2023	25.26	Incremental working capital	10.10	10.10	No	No Deviation
Public IssuesMar 2023	25.26	General Corporate Purpose	4.43	4.43	No	No Deviation
Public IssuesMar 2023	25.26	Public issue expenses	0.62	0.62	No	No Deviation
Preferential IssuesNov 2024	44.10	Capital expenditure towards expansion of new Projects or to meet working capital requirement.	41.10	41.10	No	No Deviation

₹ crore. Checked by is the agency appointed to monitor how the money is used. The reason and the comments are the company's, its audit committee's and its auditors' own words.